淡馬錫上財年投資組合價值大增24.5%至2,820億美元創新高
新加坡主權基金淡馬錫公布截至今年3月底止財年,受惠全球股市上升及旗下部分投資企業上市,轄下投資組合價值按年增長24.5%至3,810億新加坡元(約2,820億美元)創新高,升幅亦為過去十年最多,並扭轉對上一財年下跌2.3%勢頭。
淡馬錫基本投資組合中,有64%配置亞洲,主要投資於中國及新加坡。淡馬錫電訊、傳媒及科技投資聯席主管Mukul Chawla稱,疫情加速長期趨勢並塑造了淡馬錫投資定位,特別是數碼化。淡馬錫核心持股包括星展集團、建行(00939.HK)、阿里(09988.HK)(BABA.US)及渣打集團(02888.HK)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.